The US theranostics market is no longer a niche innovation; it is becoming a clinical necessity. In 2024, North America captured nearly 40% of the global theranostics market, with the U.S. contributing the largest share.
This growth is not accidental. It reflects a healthcare system responding to rising cancer incidence, demand for precision medicine, and rapid advancements in radiopharmaceutical science.
The Cancer Burden Is Reshaping Treatment Models
Prostate cancer continues to act as a key demand driver for theranostics in the U.S. The number of cases increased from 236,659 in 2021 to 299,010 in 2024, marking a significant rise in disease burden.
This sharp increase is pushing clinicians to move beyond conventional treatments and adopt targeted diagnostic-therapy combinations.
Our experts provide customized stats, segments, competitor intelligence and many more customized for your business needs: Download Now for FREE
Theranostics is stepping in where traditional oncology struggles; offering both detection and treatment through a single molecular approach.
Why the U.S. Leads the Theranostics Race
The dominance of the U.S. market is rooted in structural strengths rather than short-term trends.
The country benefits from:
- A highly developed healthcare infrastructure with advanced imaging and nuclear medicine facilities
- Strong investment in oncology research and radiopharmaceutical innovation
- Favorable regulatory pathways supporting faster approvals and commercialization
- High adoption of personalized medicine among healthcare providers
These factors create an ecosystem where innovation moves quickly from lab to patient.
Market Size and Growth Trajectory
The U.S. theranostics market is witnessing steady expansion, supported by both clinical demand and technological progress.
Key statistical highlights include:
- The U.S. accounts for over 85% of North America’s theranostics revenue
- Oncology dominates with more than 70% market share
- Radiopharmaceuticals represent the largest segment, contributing over 60% of total revenue
- The market is projected to grow at a double-digit CAGR through 2030, driven by increasing cancer cases and targeted therapy adoption
This is not a temporary spike; it is a structural shift in how diseases are diagnosed and treated.
Segment Deep Dive: Where Growth Is Concentrated
By Application: Oncology Takes the Lead
Oncology remains the backbone of theranostics in the U.S., particularly in:
- Prostate cancer
- Neuroendocrine tumors
- Thyroid cancer
Prostate cancer alone is emerging as a high-impact segment due to the growing use of PSMA-targeted therapies.
By Technology: Radiopharmaceuticals Dominate
Radiopharmaceuticals form the core of theranostics, enabling both imaging and treatment.
Alpha-emitting isotopes are gaining traction due to their ability to deliver highly targeted radiation with minimal damage to surrounding tissues.
By End User: Hospitals Drive Adoption
Hospitals and specialized cancer centers account for the majority of usage. Their access to advanced imaging technologies and trained nuclear medicine professionals accelerates adoption.
Global Market Growth
The global theranostics market size is calculated at US$ 2.42 billion in 2024, grew to US$ 2.8 billion in 2025, and is projected to reach around US$ 10.21 billion by 2034. The market is expanding at a CAGR of 15.46% between 2025 and 2034.
Innovation Is Expanding the Market Boundaries
The U.S. theranostics landscape is evolving rapidly through collaborations and technological breakthroughs.
Recent developments highlight how the ecosystem is scaling:
- Strategic partnerships are focusing on next-generation isotope production
- Companies are working on companion diagnostics to improve patient selection
- Expansion of CDMO capabilities is increasing access to radiopharmaceutical manufacturing
These innovations are not just improving outcomes—they are making theranostics more accessible across the country.
Companion Diagnostics: The Silent Growth Engine
One of the most transformative trends in the U.S. market is the rise of companion diagnostics.
These tools help identify which patients will benefit from specific therapies, reducing trial-and-error treatment approaches.
This shift improves:
- Treatment success rates
- Cost efficiency in healthcare delivery
- Patient quality of life
As a result, theranostics is becoming more precise, predictable, and patient-centric.
Regulatory Support Is Accelerating Adoption
The U.S. regulatory environment plays a critical role in market expansion.
Faster approval pathways for breakthrough therapies and increasing reimbursement support are encouraging healthcare providers to adopt theranostics solutions.
This alignment between policy and innovation is reducing barriers to entry and speeding up commercialization.
Challenges Still Exist; But They Are Shrinking
Despite strong growth, the market faces a few constraints:
- Limited availability of certain medical isotopes
- High cost of radiopharmaceutical development
- Need for specialized infrastructure and expertise
However, ongoing investments in isotope production and supply chain optimization are gradually addressing these challenges.
The Road Ahead: Precision Care Becomes Standard
The U.S. theranostics market is moving toward a future where personalized treatment is not optional—it is expected.
With rising cancer cases, especially prostate cancer, and increasing demand for targeted therapies, theranostics is set to redefine oncology care.
What makes this shift powerful is its dual capability: diagnosing disease at the molecular level and delivering therapy with unmatched precision.
Final Insight: A Defining Moment for U.S. Healthcare
The numbers tell a clear story. Rising cancer incidence, rapid technological progress, and strong institutional support are converging to reshape the treatment landscape.
Theranostics is no longer emerging; it is establishing itself as a cornerstone of modern medicine in the United States.
And if current trends continue, this approach will soon move from specialized care to standard clinical practice.
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare Web Wire is part of Towards Healthcare, which is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04